In addition, in HCC and prostate cancers, the expression of CMTM5 is negatively associated with activation of the PI3K/AKT pathway (Figure 4)48,55, which is downstream of EGFR signaling, thus suggesting that CMTM5 may inhibit tumor growth and metastasis by targeting AKT48,55. This evidence concerns the gene CMTM5 and neoplasm.